However, in this group, most patients had findings of metastatic disease (56%), which suggests that PSMA imaging is able to define two risk groups even at very low levels of PSA recurrence after prostatectomy: One with PSMA-PET/CT findings of only local tumor recurrence and excellent response to salvage treatment and a second group with findings of metastatic disease and lower response rates. The gene discussed is FOLH1; the disease is neoplasm.